JP7106625B2 - ゲノム大断片のダイレクトクローニングおよびdnaマルチ分子構築の新手法 - Google Patents
ゲノム大断片のダイレクトクローニングおよびdnaマルチ分子構築の新手法 Download PDFInfo
- Publication number
- JP7106625B2 JP7106625B2 JP2020500937A JP2020500937A JP7106625B2 JP 7106625 B2 JP7106625 B2 JP 7106625B2 JP 2020500937 A JP2020500937 A JP 2020500937A JP 2020500937 A JP2020500937 A JP 2020500937A JP 7106625 B2 JP7106625 B2 JP 7106625B2
- Authority
- JP
- Japan
- Prior art keywords
- exonuclease
- dna
- nucleic acid
- fragments
- acid molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012634 fragment Substances 0.000 title claims description 160
- 238000010367 cloning Methods 0.000 title claims description 106
- 238000000034 method Methods 0.000 title claims description 98
- 238000010276 construction Methods 0.000 title claims description 48
- 108020004414 DNA Proteins 0.000 claims description 234
- 210000004027 cell Anatomy 0.000 claims description 126
- 108060002716 Exonuclease Proteins 0.000 claims description 123
- 102000013165 exonuclease Human genes 0.000 claims description 123
- 150000007523 nucleic acids Chemical class 0.000 claims description 110
- 102000039446 nucleic acids Human genes 0.000 claims description 109
- 108020004707 nucleic acids Proteins 0.000 claims description 109
- 108090000623 proteins and genes Proteins 0.000 claims description 79
- 238000000137 annealing Methods 0.000 claims description 67
- 102000004169 proteins and genes Human genes 0.000 claims description 59
- 239000013598 vector Substances 0.000 claims description 59
- 241000588724 Escherichia coli Species 0.000 claims description 56
- 238000005215 recombination Methods 0.000 claims description 49
- 230000006798 recombination Effects 0.000 claims description 48
- 238000000338 in vitro Methods 0.000 claims description 43
- 238000002744 homologous recombination Methods 0.000 claims description 39
- 230000006801 homologous recombination Effects 0.000 claims description 39
- 230000008685 targeting Effects 0.000 claims description 27
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 26
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 26
- 239000013599 cloning vector Substances 0.000 claims description 26
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims description 24
- 238000003205 genotyping method Methods 0.000 claims description 22
- 230000001580 bacterial effect Effects 0.000 claims description 17
- 210000000349 chromosome Anatomy 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 239000013600 plasmid vector Substances 0.000 claims description 15
- 102000004594 DNA Polymerase I Human genes 0.000 claims description 14
- 108010017826 DNA Polymerase I Proteins 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- 239000002299 complementary DNA Substances 0.000 claims description 8
- 210000004962 mammalian cell Anatomy 0.000 claims description 8
- 108010055863 gene b exonuclease Proteins 0.000 claims description 7
- -1 dNTPs Proteins 0.000 claims description 6
- 102000012410 DNA Ligases Human genes 0.000 claims description 5
- 108010061982 DNA Ligases Proteins 0.000 claims description 5
- 230000006862 enzymatic digestion Effects 0.000 claims description 5
- 210000005253 yeast cell Anatomy 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 description 212
- 241001289349 Exocoetidae Species 0.000 description 83
- 108091008053 gene clusters Proteins 0.000 description 35
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 108091033409 CRISPR Proteins 0.000 description 21
- 108010055016 Rec A Recombinases Proteins 0.000 description 20
- 102000001218 Rec A Recombinases Human genes 0.000 description 20
- 238000005516 engineering process Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 102000054766 genetic haplotypes Human genes 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 230000029087 digestion Effects 0.000 description 14
- 101100316841 Escherichia phage lambda bet gene Proteins 0.000 description 12
- 229940023064 escherichia coli Drugs 0.000 description 12
- 101100226347 Escherichia phage lambda exo gene Proteins 0.000 description 10
- 108020004511 Recombinant DNA Proteins 0.000 description 10
- 210000001671 embryonic stem cell Anatomy 0.000 description 10
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 239000004189 Salinomycin Substances 0.000 description 8
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 description 8
- 238000002105 Southern blotting Methods 0.000 description 8
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 8
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- ZYWFEOZQIUMEGL-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol;phenol Chemical compound ClC(Cl)Cl.CC(C)CCO.OC1=CC=CC=C1 ZYWFEOZQIUMEGL-UHFFFAOYSA-N 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 229960001548 salinomycin Drugs 0.000 description 8
- 235000019378 salinomycin Nutrition 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000010363 gene targeting Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241001148064 Photorhabdus luminescens Species 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 101100355997 Bacillus subtilis (strain 168) recA gene Proteins 0.000 description 5
- 101100301301 Escherichia coli (strain K12) recE gene Proteins 0.000 description 5
- 101000902641 Homo sapiens Protein dpy-30 homolog Proteins 0.000 description 5
- 102100022946 Protein dpy-30 homolog Human genes 0.000 description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 description 5
- 241000187759 Streptomyces albus Species 0.000 description 5
- 229960005091 chloramphenicol Drugs 0.000 description 5
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000012154 double-distilled water Substances 0.000 description 5
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 108010067770 Endopeptidase K Proteins 0.000 description 4
- 241001646716 Escherichia coli K-12 Species 0.000 description 4
- 241000607565 Photobacterium phosphoreum Species 0.000 description 4
- 241000528933 Photobacterium phosphoreum ANT-2200 Species 0.000 description 4
- 102000018120 Recombinases Human genes 0.000 description 4
- 108010091086 Recombinases Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 101100386214 Bacillus subtilis (strain 168) dabA gene Proteins 0.000 description 3
- 238000010354 CRISPR gene editing Methods 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 101150010993 DPY30 gene Proteins 0.000 description 3
- 101100012155 Escherichia coli (strain K12) exoD gene Proteins 0.000 description 3
- 101100356230 Escherichia coli (strain K12) recT gene Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 101100355599 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mus-11 gene Proteins 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 101150006234 RAD52 gene Proteins 0.000 description 3
- 102000053062 Rad52 DNA Repair and Recombination Human genes 0.000 description 3
- 108700031762 Rad52 DNA Repair and Recombination Proteins 0.000 description 3
- 101150010310 WNT-4 gene Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- LAJRJVDLKYGLOO-NLISZJEWSA-N (3z,5r,7s,8s,11z,13r,15s,16s)-3,5,7,11,13,15-hexamethyl-8,16-bis(1,3-oxazol-5-ylmethyl)-1,9-dioxacyclohexadeca-3,11-diene-2,10-dione Chemical compound C([C@H]1[C@@H](C)C[C@H](\C=C(C)/C(=O)O[C@@H](CC=2OC=NC=2)[C@@H](C)C[C@@H](C)\C=C(C)/C(=O)O1)C)C1=CN=CO1 LAJRJVDLKYGLOO-NLISZJEWSA-N 0.000 description 2
- 241001453380 Burkholderia Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- LAJRJVDLKYGLOO-UHFFFAOYSA-N Conglobatin A Natural products O1C(=O)C(C)=CC(C)CC(C)C(CC=2OC=NC=2)OC(=O)C(C)=CC(C)CC(C)C1CC1=CN=CO1 LAJRJVDLKYGLOO-UHFFFAOYSA-N 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000193418 Paenibacillus larvae Species 0.000 description 2
- 240000001857 Phyllostachys elegans Species 0.000 description 2
- 108010030975 Polyketide Synthases Proteins 0.000 description 2
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 2
- 108010068097 Rad51 Recombinase Proteins 0.000 description 2
- 102000002490 Rad51 Recombinase Human genes 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 241001097985 Streptomyces albus subsp. albus DSM 41398 Species 0.000 description 2
- RUWSLQOIGKYPEZ-YPXRAQKDSA-N Syringolin Natural products CC(C)[C@@H](C(O)=O)NC(=O)N[C@@H](C(C)C)C(=O)N[C@H]1\C=C\CCNC(=O)\C=C\[C@H](C(C)C)NC1=O RUWSLQOIGKYPEZ-YPXRAQKDSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000012411 cloning technique Methods 0.000 description 2
- LAJRJVDLKYGLOO-ZCEOMKPZSA-N conglobatin Natural products C[C@@H]1C[C@H](C)[C@H](Cc2ocnc2)OC(=O)C(=C[C@H](C)C[C@H](C)[C@H](Cc3ocnc3)OC(=O)C(=C1)C)C LAJRJVDLKYGLOO-ZCEOMKPZSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229930189446 glidobactin Natural products 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229930192327 luminmycin Natural products 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000012743 protein tagging Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 101150079601 recA gene Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 1
- TYGJUQYJMIOZLZ-VTYVZKAMSA-N Antibiotic BU 2867TA Natural products O=C(N[C@H]1C(=O)N[C@@H](C)/C=C\C(=O)NCC[C@@H](O)C1)[C@@H](NC(=O)/C=C/C=C\CCCCCCC)[C@@H](O)C TYGJUQYJMIOZLZ-VTYVZKAMSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 238000007702 DNA assembly Methods 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 101710160937 DNA replication protein Proteins 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101100390711 Escherichia coli (strain K12) fhuA gene Proteins 0.000 description 1
- 241001302654 Escherichia coli Nissle 1917 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 101000938776 Homo sapiens ETS domain-containing transcription factor ERF Proteins 0.000 description 1
- 101000938790 Homo sapiens Eukaryotic peptide chain release factor subunit 1 Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 101150109417 NRPS gene Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150000326 Prkar1a gene Proteins 0.000 description 1
- 241000589615 Pseudomonas syringae Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001603876 Streptomyces conglobatus Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102000052548 Wnt-4 Human genes 0.000 description 1
- 108700020984 Wnt-4 Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 230000008970 bacterial immunity Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 101150102092 ccdB gene Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 108010004171 colibactin Proteins 0.000 description 1
- ZWKHDAZPVITMAI-ROUUACIJSA-N colibactin Chemical compound C[C@H]1CCC(=N1)C1=C(CC(=O)NCC(=O)c2csc(n2)C(=O)C(=O)c2csc(CNC(=O)CC3=C(C(=O)NC33CC3)C3=N[C@@H](C)CC3)n2)C2(CC2)NC1=O ZWKHDAZPVITMAI-ROUUACIJSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 101150061231 recE gene Proteins 0.000 description 1
- 230000013120 recombinational repair Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 108010038713 sevadicin Proteins 0.000 description 1
- NEHSHYOUIWBYSA-DJKXOVBDSA-N sevadicin Chemical compound C[C@@H](NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O NEHSHYOUIWBYSA-DJKXOVBDSA-N 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
- C12Q2521/319—Exonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/11—Exodeoxyribonucleases producing 5'-phosphomonoesters (3.1.11)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710177676.1A CN106995813B (zh) | 2017-03-23 | 2017-03-23 | 基因组大片段直接克隆和dna多分子组装新技术 |
| CN201710177676.1 | 2017-03-23 | ||
| PCT/CN2017/000483 WO2018170614A1 (zh) | 2017-03-23 | 2017-08-02 | 基因组大片段直接克隆和dna多分子组装新技术 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020519304A JP2020519304A (ja) | 2020-07-02 |
| JP2020519304A5 JP2020519304A5 (enExample) | 2021-09-24 |
| JP7106625B2 true JP7106625B2 (ja) | 2022-07-26 |
Family
ID=59431502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500937A Active JP7106625B2 (ja) | 2017-03-23 | 2017-08-02 | ゲノム大断片のダイレクトクローニングおよびdnaマルチ分子構築の新手法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200010867A1 (enExample) |
| EP (1) | EP3604524B1 (enExample) |
| JP (1) | JP7106625B2 (enExample) |
| KR (1) | KR102488128B1 (enExample) |
| CN (1) | CN106995813B (enExample) |
| CA (1) | CA3060585A1 (enExample) |
| DK (1) | DK3604524T3 (enExample) |
| ES (1) | ES2902210T3 (enExample) |
| WO (1) | WO2018170614A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106995813B (zh) * | 2017-03-23 | 2020-06-16 | 山东大学 | 基因组大片段直接克隆和dna多分子组装新技术 |
| CN111684069A (zh) * | 2017-12-22 | 2020-09-18 | G+Flas生命科学有限公司 | 嵌合基因组工程分子和方法 |
| CN108676847A (zh) * | 2017-12-30 | 2018-10-19 | 深圳人体密码基因科技有限公司 | 大片段基因组的捕获探针的制备方法及试剂盒 |
| CN111088275B (zh) * | 2018-10-23 | 2023-06-27 | 黄菁 | Dna大片段的克隆方法 |
| JP2022524044A (ja) * | 2019-03-08 | 2022-04-27 | ザイマージェン インコーポレイテッド | 微生物のプール型ゲノム編集 |
| CN110846239B (zh) * | 2019-11-29 | 2022-08-23 | 南京工业大学 | 具有高同源重组效率的重组解脂耶氏酵母菌及其构建方法和应用 |
| CN112852849B (zh) * | 2019-12-31 | 2023-03-14 | 湖北伯远合成生物科技有限公司 | 一种用于大片段dna无缝组装的系统及组装方法 |
| CN115349128A (zh) * | 2020-02-13 | 2022-11-15 | 齐默尔根公司 | 宏基因组文库和天然产物发现平台 |
| CN113355339B (zh) * | 2020-03-05 | 2023-01-24 | 山东大学 | 一种大型基因簇的无痕定点改造方法及其应用 |
| CN111440753A (zh) * | 2020-03-16 | 2020-07-24 | 扬州大学 | 禽致病性大肠杆菌clbH基因缺失株及其构建方法和应用 |
| CN116135982A (zh) * | 2021-11-16 | 2023-05-19 | 北京光华生明生物科技有限公司 | 用于基因片段连接的应用方法和试剂盒 |
| WO2023178544A1 (zh) * | 2022-03-23 | 2023-09-28 | 深圳华大生命科学研究院 | 表达元件组合、表达载体、宿主、应用及组装方法 |
| CN115960733B (zh) * | 2022-09-19 | 2023-11-24 | 苏州泓迅生物科技股份有限公司 | 一种用于大片段dna组装的基因工程酵母菌、构建方法及其应用 |
| CN115948445A (zh) * | 2022-12-12 | 2023-04-11 | 河南科技大学 | 谷氨酸棒杆菌CRISPR-Cpf1基因编辑系统、构建方法及应用 |
| CN116355931A (zh) * | 2023-05-29 | 2023-06-30 | 北京因诺惟康医药科技有限公司 | 一种快速分子克隆方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004535773A (ja) | 2001-02-09 | 2004-12-02 | ジーン ブリッジス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 組換え法 |
| US20070037197A1 (en) | 2005-08-11 | 2007-02-15 | Lei Young | In vitro recombination method |
| US20070037196A1 (en) | 2005-08-11 | 2007-02-15 | The J. Craig Venter Institute, Inc. | Method for in vitro recombination |
| JP2013530689A (ja) | 2010-06-10 | 2013-08-01 | ジーン ブリッジス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 直接クローニング |
| US20150072381A1 (en) | 2012-03-30 | 2015-03-12 | Shenzhen Zhonglian Biotechnology Co., Ltd | Homologous recombination-based nucleic acid molecular cloning method and related kit |
| WO2016033315A2 (en) | 2014-08-27 | 2016-03-03 | New England Biolabs, Inc. | Synthon formation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL120338A0 (en) * | 1997-02-27 | 1997-06-10 | Gesher Israel Advanced Biotecs | Single step DNA fragments assembly |
| CN106995813B (zh) * | 2017-03-23 | 2020-06-16 | 山东大学 | 基因组大片段直接克隆和dna多分子组装新技术 |
-
2017
- 2017-03-23 CN CN201710177676.1A patent/CN106995813B/zh active Active
- 2017-08-02 CA CA3060585A patent/CA3060585A1/en active Pending
- 2017-08-02 DK DK17901979.9T patent/DK3604524T3/da active
- 2017-08-02 WO PCT/CN2017/000483 patent/WO2018170614A1/zh not_active Ceased
- 2017-08-02 ES ES17901979T patent/ES2902210T3/es active Active
- 2017-08-02 KR KR1020197031095A patent/KR102488128B1/ko active Active
- 2017-08-02 EP EP17901979.9A patent/EP3604524B1/en active Active
- 2017-08-02 JP JP2020500937A patent/JP7106625B2/ja active Active
-
2019
- 2019-09-22 US US16/578,385 patent/US20200010867A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004535773A (ja) | 2001-02-09 | 2004-12-02 | ジーン ブリッジス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 組換え法 |
| US20070037197A1 (en) | 2005-08-11 | 2007-02-15 | Lei Young | In vitro recombination method |
| US20070037196A1 (en) | 2005-08-11 | 2007-02-15 | The J. Craig Venter Institute, Inc. | Method for in vitro recombination |
| JP2013530689A (ja) | 2010-06-10 | 2013-08-01 | ジーン ブリッジス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 直接クローニング |
| US20150072381A1 (en) | 2012-03-30 | 2015-03-12 | Shenzhen Zhonglian Biotechnology Co., Ltd | Homologous recombination-based nucleic acid molecular cloning method and related kit |
| WO2016033315A2 (en) | 2014-08-27 | 2016-03-03 | New England Biolabs, Inc. | Synthon formation |
Non-Patent Citations (1)
| Title |
|---|
| Nature Methods,2007年,Vol.4, No.3,pp.251-256 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3604524B1 (en) | 2021-10-06 |
| US20200010867A1 (en) | 2020-01-09 |
| WO2018170614A8 (zh) | 2018-11-01 |
| CA3060585A1 (en) | 2018-09-27 |
| EP3604524A4 (en) | 2020-04-29 |
| KR20190133200A (ko) | 2019-12-02 |
| KR102488128B1 (ko) | 2023-01-12 |
| EP3604524A1 (en) | 2020-02-05 |
| DK3604524T3 (da) | 2021-12-20 |
| WO2018170614A1 (zh) | 2018-09-27 |
| CN106995813A (zh) | 2017-08-01 |
| CN106995813B (zh) | 2020-06-16 |
| JP2020519304A (ja) | 2020-07-02 |
| ES2902210T3 (es) | 2022-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7106625B2 (ja) | ゲノム大断片のダイレクトクローニングおよびdnaマルチ分子構築の新手法 | |
| US12195732B2 (en) | Direct cloning | |
| Rajkumar et al. | Biological parts for Kluyveromyces marxianus synthetic biology | |
| Sawitzke et al. | Probing cellular processes with oligo-mediated recombination and using the knowledge gained to optimize recombineering | |
| Mosberg et al. | Improving lambda red genome engineering in Escherichia coli via rational removal of endogenous nucleases | |
| US20180127759A1 (en) | Dynamic genome engineering | |
| Wang et al. | Recent advances in strategies for the cloning of natural product biosynthetic gene clusters | |
| CN107083392A (zh) | 一种CRISPR/Cpf1基因编辑系统及其在分枝杆菌中的应用 | |
| Tear et al. | Excision of unstable artificial gene-specific inverted repeats mediates scar-free gene deletions in Escherichia coli | |
| Gelsinger et al. | Bacterial genome engineering using CRISPR RNA-guided transposases | |
| US8609374B2 (en) | Cell extract promoted cloning | |
| CN107287226B (zh) | 一种基于Cpf1的DNA构建物以及DNA体外拼接方法 | |
| WO2010113031A2 (en) | Method of altering nucleic acids | |
| Tong et al. | CRISPR-BEST: a highly efficient DSB-free base editor for filamentous actinomycetes | |
| WO2010140066A2 (en) | Method of altering nucleic acids | |
| González Linares | A CRISPR-associated transposase presents null cargo integration efficiency when targeting a transcriptionally highly active region | |
| US20240175038A1 (en) | Method for the production of seamless dna vectors | |
| Hu et al. | Plant gene modification by BAC recombineering | |
| Mosberg | Studying and improving Lambda Red recombination for genome engineering in Escherichia coli | |
| Swartjes et al. | Towards sequential conjugation-assisted laboratory evolution (SCALE) of Cas nucleases | |
| Stoltzfus | Characteristics of enzymes and cloning vectors used to create recombinant DNA | |
| WO2023070043A1 (en) | Compositions and methods for targeted editing and evolution of repetitive genetic elements | |
| JP2024509194A (ja) | インビボdnaアセンブリー及び解析 | |
| Osama et al. | In vivo cloning of plasmids in E. coli is a simpler and faster method for cloning | |
| Stoltzfus | Enzymes and Cloning Vectors Used to Create Recombinant DNA, Characteristics of |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200708 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210414 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210426 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210720 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20210720 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210803 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220404 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220711 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220713 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7106625 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |